Skip to content

The Mechanism of Hippo Pathway Mediating Macrophage Polarization in Allergic Asthma

The Mechanism of Hippo Pathway Mediating Macrophage Polarization in Allergic Asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078358
Enrollment
Unknown
Registered
2023-12-06
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Healthy control group:NA

Sponsors

the First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 69 Years

Inclusion criteria

Inclusion criteria: The diagnosis of untreated adult patients with acute episode of allergic asthma (including mild, moderate and severe) and with asthma control level graded as "fully controlled" conforms to the diagnostic criteria of the Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 Edition) and the Guidelines for the Prevention and Treatment of Allergic Asthma in China (First Edition, 2019), with appropriate reference to the Global Initiative for Asthma (GINA) (2022 Edition). The healthy control group volunteers have no positive reactions to allergen skin prick tests, negative serum allergen specific antibodies, no special medical history of allergies, no abnormal findings in physical examinations, and no history of infection in the past 2 months.

Exclusion criteria

Exclusion criteria: ? Those who do not meet the diagnostic criteria; ? Individuals who have been treated with medication for asthma, COPD, or immune diseases within one month due to other circumstances; ? Confirmed pregnancy, or suffering from serious diseases of important organs such as heart, liver, brain, lungs, kidneys, etc.; ? Acute infection within one week; ? Patients with chronic diseases such as chronic obstructive pulmonary disease, interstitial lung disease, and connective tissue disease; ? Those who do not cooperate or temporarily withdraw.

Design outcomes

Primary

MeasureTime frame
Pulmonary function;Allergen skin prick test;

Countries

China

Contacts

Public ContactLi Chaoqian

the First Affiliated Hospital of Guangxi Medical University

lichaoqiangood@163.com+86 138 0788 7867

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026